CERDELGA 84 MG
ELIGLUSTAT (ELIGLUSTAT TARTRATE) : 84 MG · DIN 02463261 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is CERDELGA?
CERDELGA 84 MG contains ELIGLUSTAT (ELIGLUSTAT TARTRATE) : 84 MG. It is listed in the Health Canada Drug Product Database under DIN 02463261, held by SANOFI-AVENTIS CANADA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Oct-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CERDELGA used for?
CERDELGA (eliglustat) is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 poor metabolizers (PMs), intermediate metabolizers (IMs) or extensive metabolizers (EMs), as determined by CYP2D6 genotype testing. It should not be used in patients genotyped as CYP2D6 ultra-rapid metabolizers (URMs) or indeterminate metabolizers.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02463261 |
|---|---|
| Brand name | CERDELGA |
| Generic / active ingredient | ELIGLUSTAT (ELIGLUSTAT TARTRATE) : 84 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 84 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A16AX10 ELIGLUSTAT |
| AHFS class | 92:92.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-Oct-2024 |
| Original market date | 2017-07-26 00:00:00 |
How is it stored and handled?
null
How is it supplied?
• Carton of 14 capsules containing 1 pack (i.e., 1 inner carton). Each pack is composed of 1 blister card of 14 capsules and a cardboard wallet. • Carton of 56 capsules containing 4 packs (i.e., 4 inner cartons). Each pack is composed of 1 blister card of 14 capsules and a cardboard wallet.
Who else supplies ELIGLUSTAT worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ELIGLUSTAT appears in 8 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.